Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas
Status:
Withdrawn
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a medication, fluvastatin, can change
melanoma to a state that is less likely to metastasize or recur.
Fluvastatin is experimental in this setting because it is not approved by the Food and Drug
Administration (FDA) for treatment or prevention of melanoma. However, fluvastatin has been
approved by the FDA for treating high cholesterol.